(Q43035431)

12 November 2017

Silibinin mode of action against hepatitis C virus: a controversy yet to be resolved (English)

1 reference

12 November 2017

1 reference

3

Alan S Perelson

1 reference

12 November 2017

1

Harel Dahari

1 reference

12 November 2017

Jeremie Guedj

2

1 reference

PMC publication ID

3677944

12 November 2017

language of work or name

English

0 references

publication date

27 June 2011

1 reference

12 November 2017

1 reference

12 November 2017

54

1 reference

12 November 2017

2

1 reference

12 November 2017

749

1 reference

Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation

12 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677944

RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677944

A perspective on modelling hepatitis C virus infection

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677944

Multiple effects of silymarin on the hepatitis C virus lifecycle

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677944

Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677944

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677944

Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfected patient

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677944

Rapid suppression of hepatitis C viremia induced by intravenous silibinin plus ribavirin

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677944

Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677944

16 August 2018

Identifiers

DOI

10.1002/HEP.24310

1 reference

12 November 2017

1 reference

PMC publication ID

3677944

12 November 2017

PubMed publication ID

21433039

1 reference

PMC publication ID

3677944